← boardnext 2026-08next 2026-12
KPTI
Karyopharm Therapeutics Incdistress 7/10 · high distress / dilution risk$6.94-3%today-35% from 52w high
Hematology 1Oncology 1
Lead: Myelofibrosis · target XPO1 · est. market ~$4B (approx, global)
Revenue
$35M
Liquidity
$91M
Runway
1.5 yrs
Shares 1y
+161%
Price & events
+4.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.3%
1D
-26.0%
1W
-28.1%
1M
-20.7%
3M
+5.3%
6M
+42.8%
1Y
-50.0%
2Y
-94.8%
5Y
-97.3%
All
Overview
- Market Cap
- $157.28M
- Volume
- 89.35K
- 52 Week Range
- $3.77 – $10.67
- Total Shares
- 22.66M
- Float Shares
- 14.81M
- Short %
- 29.20%
- % Held by Insiders
- 4.68%
- % Held by Institutions
- 83.74%
- RVOL
- 0.16x
- Beta
- 0.81
Pipeline stages · 2 programs
Selinexor, Dexamethasone, Bortezomib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 9 trials · 7 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-10-15 | Phase 3 | Selinexor | Endometrial Cancer | — | active not recruiting |
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 2 | Selinexor | Myelofibrosis | — | active not recruiting |
| 2026-12 Estimated 50% readout ~2027-01-15 | Phase 2 | Selinexor | Diffuse Large B-cell Lymphoma | — | active not recruiting |
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 2/3 | Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination | Relapsed/Refractory Diffuse Large B-cell Lymphoma | — | active not recruiting |
| 2027-04 Estimated 50% readout ~2027-05-16 | Phase 1/2 | Selinexor, Dexamethasone, Lenalidomide | Multiple Myeloma | — | active not recruiting |
Show all 9 trials · 4 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-06 Estimated 50% readout ~2027-07-16 | Phase 2 | Selinexor 60 mg, Selinexor 40 mg, Ruxolitinib | Myelofibrosis, Moderate Thrombocytopenia, Mild Thrombocytopenia | — | recruiting |
| 2028-01 Estimated 50% readout ~2028-02-15 | Phase 2 | Selinexor, Dexamethasone, Bortezomib | Multiple Myeloma, Refractory | — | recruiting |
| 2026-02-20 | Phase 3 | Selinexor, Ruxolitinib | Myelofibrosis | 353 | active not recruiting |
| 2025-12 | Phase 1/2 | Selinexor, Rituximab, Bendamustine | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | 0 | withdrawn |
Catalyst news & presentations · 8
- second half of 2026Guided 55%readoutPhase 2selinexor · Top-line data from Phase 2 SENTRY-2 trial, 60 mg cohort, at least 24 weeks follow-upSEC 8-K
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2026readoutPhase 3selinexor · Top-line data from Phase 3 XPORT-EC-042 trialSEC 8-K
- on or about March 26, 2026trial initiationsecondaryClosing of private placement with RA CapitalSEC 8-K
- 2026-03-24partnershipEntered securities purchase agreement with RA Capital for private placement of shares and warrantsSEC 8-K
- March 2026readoutPhase 3selinexor · Top-line data from Phase 3 SENTRY trialSEC 8-K
- second half of 2025readoutPhase 3selinexor · Top-line results from Phase 3 SENTRY trial evaluating selinexor plus ruxolitinib vs placebo plus ruxolitinib in JAKi naïve patients.SEC 8-K
- 2024-10-31fda agreementselinexor · FDA agreement to replace TSS50 with Abs-TSS as co-primary endpoint in Phase 3 SENTRY trial.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $14 (+95% upside) · 6 analysts
- 2026-05-06HC Wainwright & Co.Buy
- 2026-04-27Piper SandlerOverweight
- 2026-03-30Piper SandlerOverweight
- 2026-03-25BairdOutperform
- 2026-03-25HC Wainwright & Co.Buy
- 2026-03-10Rodman & RenshawBuy
Competitors — XPO1
- none identified
Recent news
- 2026-07-23KPTI Q2'26 Earnings: revenue estimate is 33.12M USD - TradingView
- 2026-07-22Karyopharm Therapeutics Inc (NASDAQ: KPTI) Share Price, KPTI Stock News, KPTI Share Price & Updates - Kalkine
- 2026-07-21Karyopharm: "Hold" Slow XPOVIO U.S. Sales But 2026 Milestones Still On Deck (KPTI) - Seeking Alpha
- 2026-07-21Karyopharm Therapeutics: Balance Sheet Poor But Catalysts Ahead (NASDAQ:KPTI) - Seeking Alpha
- 2026-07-21Karyopharm Therapeutics: Balance Sheet Poor But Catalysts Ahead (NASDAQ:KPTI) - Seeking Alpha
- 2026-07-21Karyopharm Pharmaceuticals (KPTI) Sees 21% Drop Amid Leadership Cash Retention Program - GuruFocus
- 2026-07-20Karyopharm Pharmaceuticals (KPTI) Sees 21% Drop Amid Leadership Cash Retention Program - GuruFocus
- 2026-07-20Karyopharm Pharmaceuticals (KPTI) Sees 21% Drop Amid Leadership Cash Retention Program - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.